Literature DB >> 22932961

What factors determine whether a woman becomes depressed during the perimenopause?

Zoe Gibbs1, Stuart Lee, Jayashri Kulkarni.   

Abstract

Perimenopause has long been associated with psychological distress, both anecdotally and clinically. Research has identified this time as a period of increased risk for both first-episode depression and for depression reoccurrence. However, we know that the majority of women do not experience these difficulties during perimenopause. This review examines the current research literature looking at the factors associated with depression during perimenopause, with a view to identifying those factors which are protective and those factors which predict increased risk. From the literature, it is evident that some women have a hormonal vulnerability to mood disorders. However, this does not account for the phenomenon of perimenopausal depression in and of itself. Rather, there appears to be a complex interplay between hormonal vulnerability, the psychosocial resources one has (coping skills and social support), their overall well-being (exercise and other lifestyle factors) and the demands on their coping resources (stressful life events). The complexity of the relationship between perimenopause and depression means that there is a need to look beyond either as a sole explanation of mood during midlife. Education is required for both general practitioners and for women regarding the individual risks of psychological distress during perimenopause, as well as the knowledge of the life factors which we know to be protective.

Entities:  

Mesh:

Year:  2012        PMID: 22932961     DOI: 10.1007/s00737-012-0304-0

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  9 in total

Review 1.  Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease.

Authors:  Joyce T Bromberger; Cynthia Neill Epperson
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

2.  Paroxetine versus Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.

Authors:  Camilla Callegari; Marta Ielmini; Ivano Caselli; Giulia Lucca; Celeste Isella; Marcello Diurni; Fabiana Pettenon; Nicola Poloni
Journal:  Psychopharmacol Bull       Date:  2019-02-15

Review 3.  Impact of menstrual cycle events on bipolar disorder course: a narrative review of current evidence.

Authors:  Elena Aragno; Andrea Fagiolini; Alessandro Cuomo; Elena Paschetta; Giuseppe Maina; Gianluca Rosso
Journal:  Arch Womens Ment Health       Date:  2022-03-02       Impact factor: 3.633

4.  Maternal Mental Health: Where Should Our Research and Policy Priorities Be?

Authors:  Jennifer L Payne; Debra Umberson; Erin Kellogg
Journal:  NAM Perspect       Date:  2020-11-23

5.  Metabolic and hormone influences on emotion processing during menopause.

Authors:  Alison Berent-Spillson; Courtney Marsh; Carol Persad; John Randolph; Jon-Kar Zubieta; Yolanda Smith
Journal:  Psychoneuroendocrinology       Date:  2016-09-05       Impact factor: 4.905

6.  Development and validation of a new rating scale for perimenopausal depression-the Meno-D.

Authors:  Jayashri Kulkarni; Emorfia Gavrilidis; Abdul-Rahman Hudaib; Caitlin Bleeker; Roisin Worsley; Caroline Gurvich
Journal:  Transl Psychiatry       Date:  2018-06-28       Impact factor: 6.222

7.  Effect of Time Management Training on Anxiety, Depression, and Sleep Quality.

Authors:  Ping Wang; Xiaochun Wang
Journal:  Iran J Public Health       Date:  2018-12       Impact factor: 1.429

8.  Religiosity and Depression at Midlife: A Prospective Study.

Authors:  Micheline R Anderson; Priya Wickramaratne; Connie Svob; Lisa Miller
Journal:  Religions (Basel)       Date:  2020-12-31

9.  Prolonged secretion of cortisol as a possible mechanism underlying stress and depressive behaviour.

Authors:  Dong-Dong Qin; Joshua Rizak; Xiao-Li Feng; Shang-Chuan Yang; Long-Bao Lü; Lei Pan; Yong Yin; Xin-Tian Hu
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.